3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Colorectal Neoplasms
57
Ovarian Neoplasms
37
Carcinoma, Hepatocellular
35
Neoplasms
25
Fallopian Tube Neoplasms
20
Carcinoma, Non-Small-Cell Lung
19
Endometrial Neoplasms
13
Glioblastoma
11
Breast Neoplasms
11
Brain Neoplasms
11
Neoplasm Metastasis
9
Colonic Neoplasms
9
Uterine Cervical Neoplasms
8
Lung Neoplasms
8
Liver Neoplasms
7
Stomach Neoplasms
6
Rectal Neoplasms
6
Glioma
6
Biliary Tract Neoplasms
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Recurrence
3
Peritoneal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Interventions
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
Paclitaxel
1
Nivolumab
1
Ipilimumab
1
Gemcitabine
1
Doxorubicin
1
Dexamethasone
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma, Clear Cell
×
Bevacizumab
×
90 days
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled